EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieOpen Access · CC BY 4.0

Safety and Pharmacokinetics of Quizartinib Combination Therapy With Standard Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results from Two Phase 1 Trials in Japan and China

Junyuan Qi, Ilseung Choi, Shuichi Ota, Satoshi Ichikawa, Naohito Fujishima, Hiroatsu Iida, Isamu Sugiura, Koichi Sugiura, Yasuharu Murata, Hiroyuki Inoue, Shoichi Ohwada, Jianxiang Wang

Clinical Pharmacology in Drug Development · 2024

DOI: 10.1002/cpdd.1353 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Junyuan Qi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Phenylurea Compounds, Benzothiazoles, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Quizartinib is a potent, oral, second‐generation, selective type II FMS‐like receptor tyrosine kinase 3 (FLT3) inhibitor. It has shown improved overall survival in a randomized, multinational, Phase 3 (QuANTUM‐First) study in patients with FLT3 ‐internal tandem duplication (ITD)‐positive newly diagnosed acute myeloid leukemia. We conducted 2 Phase 1b studies in Japan and China to evaluate the safety, pharmacokinetics, and efficacy of quizartinib in combination with standard induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia. Quizartinib was started at a dose level of 20 mg/day and then escalated to 40 mg/day, the dose used in the Phase 3 study. Seven patients were enrolled according to the 3 + 3 dose‐escalation method in each study, including 3 patients who were FLT3 ‐ITD positive. No dose‐limiting toxicities were observed at dose levels up to 40 mg/day in both studies. Grade 3 or higher, quizartinib‐related, treatment‐emergent adverse events included febrile neutropenia, hematologic toxicities, and infections. QT prolongation on electrocardiogram was observed in 5 patients. The pharmacokinetics of quizartinib and its metabolite AC886 were similar between the studies and consistent with previous findings in the United States. We confirmed the tolerability of Japanese and Chinese patients to the dose of quizartinib and chemotherapy regimens used in the QuANTUM‐First study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcutePhenylurea CompoundsBenzothiazolesAntineoplastic Combined Chemotherapy Protocolsfms-Like Tyrosine Kinase 3Consolidation ChemotherapyHumansMaleMiddle AgedFemaleChinaAdultJapanAgedInduction ChemotherapyDose-Response Relationship, Drug

Stichwörter der Autor:innen

FLT3 inhibitorFLT3‐ITD mutationacute myeloid leukemiapharmacokineticsquizartinib

Substanzen

quizartinibPhenylurea CompoundsBenzothiazolesfms-Like Tyrosine Kinase 3FLT3 protein, human

Autor:innen und Institutionen

  • Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
  • National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
  • Sapporo Hokuyu Hospital, Sapporo, Japan.
  • Tohoku University Hospital, Sendai, Japan.
  • Noshiro Kousei Medical Center, Akita, Japan.
  • National Hospital Organization Nagoya Medical Center, Nagoya, Japan.

Zitieren

APA

Qi, J., Choi, I., Ota, S., Ichikawa, S., Fujishima, N., Iida, H., Sugiura, I., Sugiura, K., Murata, Y., Inoue, H., Ohwada, S., & Wang, J. (2024). Safety and Pharmacokinetics of Quizartinib Combination Therapy With Standard Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results from Two Phase 1 Trials in Japan and China. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1353

Vancouver

Qi J, Choi I, Ota S, Ichikawa S, Fujishima N, Iida H, et al. Safety and Pharmacokinetics of Quizartinib Combination Therapy With Standard Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results from Two Phase 1 Trials in Japan and China. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1353

BibTeX
@article{Qi2024,
  author = {Qi, Junyuan and Choi, Ilseung and Ota, Shuichi and Ichikawa, Satoshi and Fujishima, Naohito and Iida, Hiroatsu and Sugiura, Isamu and Sugiura, Koichi and Murata, Yasuharu and Inoue, Hiroyuki and Ohwada, Shoichi and Wang, Jianxiang},
  title = {Safety and Pharmacokinetics of Quizartinib Combination Therapy With Standard Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results from Two Phase 1 Trials in Japan and China},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2024},
  doi = {10.1002/cpdd.1353}
}
Kostenlos starten →